Abstract
Introduction
Fingolimod is an immunomodulating agent used in multiple sclerosis (MS). It is a sphingosine-1-phosphate (S1P) receptor agonist prescribed for relapsing forms of MS to delay onset of physical disability. As fingolimod is known to cause first-dose bradycardia, telemetry is recommended for the first 6 h post-dose. We present the first reported case of deliberate fingolimod overdose requiring atropine administration for bradycardia and hemodynamic instability.
Case report
A 33-year-old woman ingested 14 mg of fingolimod and 2 g of phenoxymethylpenicillin. After presenting to the emergency department 19 h later, she was initially hemodynamically stable (heart rate (HR) 60, blood pressure (BP) 113/89 mmHg). Two hours later, she then developed bradycardia (HR 48) and hypotension (87/57 mmHg). Despite intravenous fluids, stabilisation was only achieved after administration of atropine (300 μg). She was then admitted to the intensive care unit (ICU) for further monitoring where another episode of bradycardia and hypotension required atropine. She was monitored in the ICU for 48 h and then discharged on day 5 with no further episodes.
Discussion
Fingolimod is known to cause bradycardia in the first 6 h post first therapeutic dose. Following intentional overdose, onset of bradycardia occurred at 21 h post-ingestion and was associated with hypotension. Atropine was successful in treating bradycardia and associated hypotension.
References
Brinkmann V, Lynch KR (2002) FTY720: targeting G-protein-coupled receptors for sphingosine 1-phosphate in transplantation and autoimmunity. Current Opin Immunol 14:569–575
Hla T (2003) Signaling and biological actions of sphingosine-1-phosphate. Pharmacol Res 47:401–407
Espinosa PS, Berger JR (2011) Delayed fingolimod-associated asystole. Multiple Sclerosis Journal 17(11):1387–1389
Faber H, Fischer HJ, Weber F (2013) Prolonged and symptomatic bradycardia following a single dose of fingolimod. Mult Scler 19(1):126–128
Koyrakh L, Roman MI, Brinkmann V, Wickman K (2005) The heart rate decrease caused by acute FTY720 administration is medicated by the G protein-gated potassium channel I. Am J Transplant 5:529–5367
Kovarik JM, Hartmann S, Bartlett M et al (2007) Oral-intravenous crossover study of fingolimod pharmacokinetics, lymphocyte responses and cardiac effects. Biopharm Drug Dispos 28:97–104
David OJ, Kovarik JM, Schmouder RL (2012) Clinical pharmacokinetics of fingolimod. Clin Pharmacokinet 51(1):15–28
Tolle M, Levkau B, Keul P et al (2005) Immunomodulator FTY720 induces eNOS-dependent arterial vasodilation via the lysophospholipid receptor S1P3. Circ Res 96(8):913–920
Kovarik JM, Riviere GJ, Neddermann D et al (2008) A mechanistic study to assess whether isoproterenol can reverse the negative chronotropic effect of fingolimod. J Clin Pharmacol 48(3):303–310
Naranjo CA, Busto U, Seller EM et al (1981) A method for estimating the probability of adverse drug reactions. Clin Pharmacol 30(2):239–245
Conflict of Interest
The authors report no conflict of interest. The authors alone are responsible for the content and writing of the paper.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Stephenson, M., Wong, A., Rotella, J.A. et al. Deliberate Fingolimod Overdose Presenting with Delayed Hypotension and Bradycardia Responsive to Atropine. J. Med. Toxicol. 10, 215–218 (2014). https://doi.org/10.1007/s13181-013-0354-3
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13181-013-0354-3